Sravan Emany brings capital markets and commercial-stage, rare disease expertise as the Company advances towards commercialization Andrew Miller adds deep clinical development and product approval exp ...

Sravan Emany brings capital markets and commercial-stage, rare disease expertise as the Company advances towards commercializationAndrew Miller ...

The U.S. Food and Drug Administration approved Cobenfy on September 26, 2024, making it the first schizophrenia drug with a fundamentally new mechanism of action in more than half a century. Built on ...

Bristol-Myers' total return more than doubled S&P 500 performance since I opened my Long position. Fast-forward to 2026, all eyes should be on the upcoming $30B patent cliff as the Growth portfolio ...

Bristol Myers Squibb Co. forecast 2026 sales and profit above Wall Street’s expectations, a sign that the company’s newer medicines are helping stem the losses from its older drugs that are losing ...

Feb 4 (Reuters) - Drug developer Eikon ‍Therapeutics said on Wednesday it had raised $381.2 million in its U.S. initial public offering, selling about 21.2 million shares priced at $18 apiece. This ...

CAMBRIDGE, England & DETROIT--(BUSINESS WIRE)--Cycle Group Holdings Limited (“Cycle”) is delighted to announce it has completed the acquisition of NASDAQ-listed Applied Therapeutics, Inc. (NASDAQ: ...

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Eikon Therapeutics Inc. filed for an initial public offering to help fund its advanced pipeline of cancer drugs. The company plans for its shares to trade on the Nasdaq Global Market under the symbol ...

Just in time for the holidays, on December 15, 2025, the U.S. Food and Drug Administration (“FDA”) Office of Prescription Drug Promotion (“OPDP”) issued an untitled letter (the “Letter”) to Karuna ...